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PREFACE 
 “We have the self-awareness to be honest with ourselves to say, “we have been part of the 
problem, and we have to be part of the solution” 
~Jonathan Brown, CEO, Indian Stream Health Center 
Regarding opioid prescribing and efforts to combat the opioid epidemic 
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ABSTRACT 
The concurrent use of opioids and benzodiazepines (BZDs poses a formidable challenge for 
clinicians who manage chronic pain. While the escalating use of opioid analgesics for the 
treatment of chronic pain and the concomitant rise in opioid-related abuse and misuse are 
widely recognized trends, the contribution of combination use of BZDs, alcohol, and/or other 
sedative agents to opioid-related morbidity and mortality is underappreciated, even when 
these agents are used appropriately. Patients with chronic pain who use opioid analgesics 
along with BZDs have a defined increase in rates of adverse events, overdose, and death, 
warranting close monitoring. To improve patient outcomes, ongoing screening for aberrant 
behavior, monitoring of treatment compliance, documenting medical necessity, and e 
adjusting treatment in response to clinical changes are essential. National and state 
guidelines recommend that patients on chronic opioid therapy (COT) should periodically 
undergo urine drug testing and a review of prescription drug monitoring program to confirm 
adherence to the treatment plan. These guidelines also recommend reviewing the 
prevalence and pharmacologic consequences of BZDs among patients on COT. This DNP 
Project evaluated the effectiveness of the implementation of a quarterly triad tool (QTT), 
which included (a) current urine drug testing and (b) prescription drug monitoring, with (c) 
the addition of medication reconciliation for concomitant BZD use (CBU) on mitigation of 
adverse event risks in patients treated for chronic pain in a pain clinic in central Indiana. One 
of six providers did not adopt the practice change; but 151 of 154 patients were screened 
using the QTT, and 24 (15.89%) had CBU detected. Documentation of risk education 
increased from 25% pre-intervention to 100% post-intervention (X2(1) = 10.59, p = .001). 
Follow-up plan documentation also increased to a statistically significant level: 5% pre-
intervention to 75% post-intervention (X2(1) = 8.24, p = .004). 
Keywords: quarterly triad tool, opioids, benzodiazepines, chronic pain 
viii 
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CHAPTER 1 
INTRODUCTION 
Background 
Chronic pain continues to be a multidimensional problem for people in the United States 
of America. The experience of pain has been recognized as a national public health problem 
with profound physical, emotional and societal costs (U.S. Department of Health and Human 
Services [USDHHS], 2018). Today, chronic pain affects an estimated 50 million U.S. adults and 
as many as 19.6 million of those adults experience high-impact chronic pain that interferes with 
daily life of work activities (USDHHS, 2018). Primary care providers, as well as pain 
management specialists, often rely on opioids to control chronic pain. However, the use of these 
potent medications must be balanced against their risk for harmful adverse effects, which range 
from constipation to respiratory arrest. In particular, the prevalence of psychological 
dependence on opioids has increased at an unprecedented rate in many regions throughout the 
United States (USDHHS, 2018). This chapter will provide a summary of the background and 
significance of the recent “opioid epidemic” and describe the purpose of this project in the 
context of chronic pain management. 
Statement of the Problem 
In the US, the increased use of prescription opioids and the resulting potential for 
addiction and overdose impose substantial public health burden of morbidity, mortality and 
economic costs (Sun et al., 2017). From 1999-2014, more than 165,000 persons died from 
overdose related to opioid pain medication in the United states (Centers for Disease Control and 
Prevention [CDC], 2016). According to Sun et al. (2017), approximately 30% of fatal “opioid” 
overdoses also involve benzodiazepines, which are often used concurrently with opioids, raising 
the possibility that some of the increase in opioid related deaths could be caused by concurrent 
benzodiazepine/opioid use over time.  
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Data from the Literature Supporting Need for the Project 
In addition to the overuse and abuse of opioids, the use of non-opioid substances (e.g., 
benzodiazepines) to manage the psychological effects of chronic pain adds an additional layer 
of complexity to the opioid epidemic. Benzodiazepines have been commonly used to treat 
anxiety and insomnia in patients with chronic pain. However, combined benzodiazepine and 
opioid use is increasingly implicated in emergency department visits and drug overdoses (Park 
et al., 2016). Moreover, use of benzodiazepines without a prescription has been associated with 
increased risk for the development of opioid use disorder (Park et al., 2016). This is mainly due 
to the enhanced pain relief, increased sense of euphoria, and availability of these substances in 
the primary care setting and through non-prescribed means. Sun et al. (2017) found that 9% of 
opioid users also used a benzodiazepine in 2001, increasing to 17% in 2013 (80% relative 
increase).  
According to Park et al. (2016), substance use disorder treatment admissions reporting 
both benzodiazepine and opioid analgesic use increased 570% between 2000 and 2010, 
whereas admissions that involved neither of these drugs decreased by 9.6%. These admissions 
increase healthcare costs, which result in devastation of households, governments, and the 
private sector.  Prospective gains of mitigating combine benzodiazepine-opioid-related 
admissions include healthcare costs savings and lower spending on other cascade expenses 
(e.g., law enforcement). This can result in overall economic returns to households, the private 
sector and the government, allowing allocation of funds to other initiatives (e.g., public school 
systems).   
In summary, chronic pain and opioid use disorder, particularly when combined with the 
use of benzodiazepines, are two conditions that have potentially devastating consequences for 
patients, their families, their communities, and the healthcare system. As evidence suggests, 
the apparent need for an evidence-based approach in identifying and mitigating this risk for 
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opioid use disorder, while effectively managing chronic pain, is crucial. Pain management 
providers who routinely care for patients on COT should engage in a routine assessment and 
evaluation of risk factors which could consequently result in an overall reduction of deaths 
affiliated with prescription opioids.  
Strategies to prevent opioid-related deaths include (a) routinely evaluating for risk factors 
of opioid overdose or addiction, (b) checking prescription drug monitoring programs (PDMP) for 
concurrent use of opioids and other controlled substances, and (c) conducting urine drug screen 
(UDS) to confirm compliance with treatment plans (CDC, 2016). However, these efforts have 
been largely unsuccessful due to limited access to pain management experts, inconsistent use 
of opioid surveillance programs, and variable social support for responsible opioid use. 
Leichtling et al. (2016) stated that in most states, PDMPS are not yet accessed by prescribers 
routinely and consistently; to address this gap, many states have mandated the use of PDMP, 
though conditions under which use is required vary greatly. 
 Prescription drug monitoring programs (PDMPs) are a key element in the identification 
of concurrent prescriptions of controlled substances. Guidelines from the American Pain Society 
recommend individual risk gradation with patients receiving long-term opioids to determine 
frequency of monitoring, with a variety of tools (e.g., monitoring stable patients at least every 
three to six months). The CDC guidelines for opioid prescribing in patients in COT recommend 
PDMP review ranging from each time of prescribing to every 3 months. A qualitative study by 
Leichtling et al. (2016) revealed that PDMP use varied from consistent monitoring on a 
scheduled basis to checking the PDMP only on suspicion of misuse, with inconsistent use 
reported particularly among short time prescribers and with existing patients of long-term 
prescribers. This evidence supports the need for utilization of a standardized approach to using 
PDMP with the hypothesized primary goal of promoting compliance and a secondary goal of risk 
identification and mitigation with regards to concomitant benzodiazepine-opioid use (CBU). 
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Data from the Clinical Agency Supporting Need for the Project 
The clinical setting for this project was an outpatient pain management center in Central 
Indiana. Providers at this facility included three pain management physicians, two physician 
assistants (PAs), and one adult geriatric primary care nurse practitioner (AGPCNP). Although 
provider patient loads vary by the type of visit; new patient visit or monthly return, on average 
about 20 to 25 patients on long-term opioids are seen for their quarterly visit (third month visit).  
A comprehensive approach to pain management including non-pharmacological interventions, 
physical therapy, and analgesics (opioid and non-opioid) was utilized as the standard of 
practice. However, there was no standardized system for monitoring patients on COT for 
features of opioid use disorder and concurrent benzodiazepine use. Providers at this site 
typically used either a random urine drug screen (UDS) or PDMP, which screened for the 
quantity of opioids that had been prescribed and distributed to the patient over a period of time. 
Informal patterns of assessing CBU likely linked to a review of medication reconciliation at each 
clinic visit and a random UDS were apparent in the preliminary data. Yet, consistency was not 
shown in the evaluation of CBU at each visit. This project was necessary at this facility given 
that several patients currently receiving chronic opioid therapy (COT) were also taking 
benzodiazepines. As a facility, there was a drive to promote safe opioid prescribing with 
adherence to the recommended CDC guidelines. As a part of this initiative, the leadership had 
incorporated a psychologist to address cognitive behavioral treatment (CBT) options that would 
eliminate the need for benzodiazepine use and allow for the lowest dose of opioid use for 
chronic pain management. Park et al. (2016) found that approximately 40% of patients who are 
prescribed an opioid are also prescribed a benzodiazepine. This same pattern of CBU had been 
noted at the facility, prompting administrative staff to push providers to evaluate for CBU and to 
utilize evidence-based practice (EBP) options to eliminate CBU. In an attempt to improve patient 
safety by decreasing concurrent opioid and benzodiazepine use, a discussion with the clinic 
administrator revealed that this project was imperative. 
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Purpose of the Evidence-Based Practice Project 
Compelling Clinical Question 
The compelling clinical query that this project addresses was as follows: What evidence-
based strategies are effective in increasing healthcare providers’ use of PDMPs, UDSs, and 
CBU monitoring among patients on COT? A literature search and appraisal allowed for an 
evidence-based approach to the creation and utility of a tool that was utilized in the clinic by 
providers during their routine quarterly visits during the time of project implementation. 
PICOT Question 
The PICOT question for this evidence-based practice project was as follows Among pain 
management providers (P), does the use of a standardized quarterly triad tool (QTT) consisting 
of PDMP, UDS, and medication reconciliation for CBU (I), compared to the current practice of 
PDMP or UDS only (C), increase the monitoring of CBU and providers initiation of a 
benzodiazepine specific follow up plan (O) over a 90-day period (T)? 
Significance of the EBP Project 
The 2016 CDC guideline for prescribing opioids for chronic pain includes a 
recommendation for the routine evaluation of risk factors for opioid-related harms and ways to 
mitigate patient risk (CDC, 2016).The guidelines also recommend reviewing of PDMP data, 
using urine drug testing, and avoidance of co-prescribing benzodiazepines whenever possible. 
The intervention within this EBP project was intended to promote the assessment of CBU by 
providers, with the goal of promoting provider adherence to the use of the tool and ultimately 
reducing opioid and benzodiazepine co-prescribing among patients on long-term opioid therapy. 
The intervention was also intended to trigger follow up planning of affected patients by 
providers. 
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CHAPTER 2 
THEORETICAL FRAMEWORK, EBP MODEL, AND REVIEW OF LITERATURE 
Theoretical Framework 
With the consideration of the necessity for a systematic approach to aid in the success 
of the project, the DNP student facilitator elected to incorporate John Kotter’s model of change 
as the theoretical framework to guide practice change. The following narrative provides an 
overview of Kotter’s model and details its application to this EBP project.   
Overview of Theoretical Framework 
Based on information gathered during interviews from more than 100 organizations in 
the process of large-scale change, John Kotter, in his work with Dan Cohen, proposed that the 
key to organizational change was founded in helping people to feel differently (i.e., appealing to 
their emotions) (Melynk & Fineout-Overholt, 2015). Kotter asserted that individuals change their 
behavior less when they are given the facts or analyses that change their thinking than when 
individuals are shown truths that influence their feelings. (Melynk & Fineout-Overholt, 2015). 
This model was determined to be ideal for the implementation of this project due to its clarity of 
purpose and the assertion of the seeing, feeling and changing pattern necessary for successful 
behavioral change. It is outlined in eight steps which include; (a) creating a sense of urgency for 
the project, (b)  building a guiding coalition, (c) forming a strategic vision and initiatives, (d) 
enlisting a voluntary army and buy in, (e) empowering others to action and removing all barriers 
of behavioral change, (f) generating short-term wins, (g) sustaining acceleration, and (h) 
nourishing the new culture to allow for change transmission, where the new change becomes 
the norm (Kotter International, Inc., n.d.)  
Application of Theoretical Framework to EBP Project 
The first step of the Kotter’s model of change is the creation of a sense of urgency. In 
this step, the DNP student facilitator helps others to see the need for change through a bold, 
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aspirational opportunity statement that communicates the importance of acting immediately 
(Kotter International, Inc., n.d.). Melnyk and Fineout-Overholt (2015) stated that the creation of a 
sense of urgency is especially important when individuals in an organization have been in a rut 
or a period of complacency for some time. A sense of urgency was established after the DNP 
student discussed national necessity data as indicated in Chapter 1 of this DNP Project Report, 
which included increased risk for overdose, death, and hospital admission, as well as healthcare 
cost. Internal data of patients from the clinic who were impacted was also shared.  
 A preliminary review conducted in September 2018 revealed that approximately 30% of 
patients who were on COT were also taking benzodiazepines. Although there was an effort by 
the prescribing providers to limit concurrent opioid-benzodiazepine use (CBU), there also was 
considerable variation in the processes of identifying CBU, as well as the timing of screening 
and designated intervention across the span of providers. It became evident that there was a 
need for a streamlined process which would not only identify CBU but also outline a well-defined 
patient-centric follow up plan for affected patients. A story was shared by the DNP student of 
several patients who had legitimate chronic pain issues and had to give up their pain contracts 
and opioid therapy because they felt that their anxiety concerns and need for benzodiazepine 
use was much more weighted. These were patients who not only could have been identified 
with the proposed intervention, but with a well-documented follow up plan, they would have 
maintained their therapeutic relationship with the providers within reasonable accommodation 
and utilized a referral to the inhouse pain psychotherapist or an external psychotherapist for 
follow up.  
The second step in Kotter’s change model involves the selection of a strong team of 
individuals who can guide change (Melynk & Fineout-Overholt, 2015). The DNP student 
facilitator identified a medical assistant champion who had a vast knowledge of the processes, 
respect and trust with other staff and was vested in the outcomes of the project with regards to 
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the utility of both the PDMP and the UDS in the identification on CBU. The medical assistant 
champion was also the head medical assistant at the clinic setting  
Step three entails the creation of a vision and realistic implementation strategy for 
bringing the vision to fruition (Melynk & Fineout-Overholt, 2015). Per the stipulation of the 
project, the idealistic timeframe for the project implementation was 90 days. To allow for ease of 
documentation, an already existing auto-text quick step option in the electronic medical record 
was utilized to aide with the quick download of the triad for documentation into patient charts. 
The vision for the project was discussed with the providers and the support staff. 
Step four necessitates communicating the vision (Melynk & Fineout-Overholt, 2015). 
This was done through sharing the heartfelt stories of patients, the same stories that were 
shared to communicate the sense of urgency and the need to go beyond “just abiding with the 
guidelines” but including individualized patient outcomes which would ultimately improve safety 
outcomes but also promote retention and patient satisfaction within the operational context.  
Step five involves staff empowerment for behavioral change and elimination of barriers 
that inhibit successful change (Melynk & Fineout-Overholt, 2015). The project did not require 
any financial commitment or additional staff hours for implementation, the use of the auto-text 
option also made the adaptation of the quarterly triad tool into routine EMR documentation 
made it much easier for the providers to incorporate it. 
Step six emphasizes the importance of celebrating short-term successes. Biweekly data 
sharing sessions were planned to demonstrate compliance with use of the quarterly triad tool 
and to further motivate the providers and staff to move toward Kotter’s seventh step of change.  
Step seven highlights ongoing persistence needed to make the vision a reality. Initially, 
not all providers were on board, in fact, only two out of four providers were willing to be a part of 
the project, with the attitude of aiding the DNP student in seeing the project to completion rather 
than changing practice outcomes.  However, the DNP student planned persistence to making 
the vision a reality and cementing the practice change. This stage of the change process was 
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supported by the initial timeframe of piloting the change. Because the implementation time was 
limited to 90 days, the DNP student was able to convince more providers to become part of the 
project. 
Step eight, which is the last step, highlights the necessity for nourishment of the new 
culture to make it last. Melynk and Fineout-Overholt (2015), stipulated that it is important to 
nourish the new culture to make the change last even if the leadership experiences transitions. 
This nourishment is essential if the new culture and behavior are to be sustained (Melynk & 
Fineout-Overholt, 2015). The DNP student developed a plan for sustaining the practice change 
but buy in for the continued change by other prescribing providers was determined to be more 
likely if the practice change was streamlined, was easily incorporated into current practice 
change, resulted in positive outcomes, and did not negatively impact the flow of patient care 
within the clinic setting. 
Strengths and Limitations of Theoretical Framework for EBP Project 
The main strength of the Kotter model for this EBP was that it maps out key steps and 
components that are necessary for change. The model also addressed the emotional imperative 
of change by ascertaining that there is a seeing and feeling and changing pattern necessary for 
behavioral modification. This was very clear in the project implementation, as the DNP student 
facilitator was able to use each aspect of the model as stipulated in the application segment of 
this chapter.  
A limitation of using the Kotter model was hat the assumption that positions change with 
the successful transition from one step to the next may not be idealistic. At times, the vision 
could precede the communication of urgency, and the process of communicating the vision 
might overlap with the communication of the sense of urgency. Furthermore, it was noted that a 
few of the steps overlap. There was also the insinuation of the trickle-down change aspect in the 
selection of the leadership team. While this was in itself a strength with regards to steering of 
goals and the vision, it could also be viewed as a weakness in that it was exclusionary, and 
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those employees who were not included in the leadership team could view themselves as 
puppets and become detached as they feel less ownership.  
Evidence-based Practice Model 
Early in the EBP movement, healthcare scientists, including many nurse scientists 
developed models to organize our thinking about EBP and understand how various aspects of 
EBP work together to improve care and outcomes (Melynk & Fineout-Overholt, 2015). These 
models guide the design and implementation of approaches intended to strengthen evidence-
based decision making and help clinicians implement an evidence-based change in practice 
(Melynk & Fineout-Overholt, 2015). To facilitate evidence translation into clinical practice within 
this DNP project, the PARHIS model was incorporated. The DNP student facilitator used the 
PARIHS model to facilitate practice change by incorporating research evidence in the pain 
management context, and utilizing already existing components of the culture, structure, 
resources and the clinical staff to implement change. 
Overview of EBP Model 
The PARIHS (Promoting Action on Research Implementation in Health Services) 
framework was used in the design and implementation of this EBP project. The PARIHS 
framework posits an outline for evidence implementation. It is comprised of three interacting 
core elements: evidence (E) ‘codified and non-codified sources of knowledge’ as perceived by 
core stakeholders; context (C) the quality of the environment or setting in which the research is 
implemented; and facilitation (F) a ‘technique by which one person makes things easier for 
others,’ achieved through ‘support to help people change their attitudes, habits, skills and ways 
of thinking and working’ (Helfrich et al., 2010). An integral component of the PARIHS framework 
is the assumption that successful implementation of evidence is a function on these three key 
components, where each factor can be rated on a scale from high to low and where high ratings 
are likely to produce successful implementation results. 
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In the PARIHS framework, evidence consists of four sub-elements, corresponding to 
four main sources of evidence: (a) research evidence from studies and clinical practice 
guidelines including, formal experiments; (b) clinical experience or related professional 
knowledge; (c) patient preferences and experiences; and (d) locally derived information or data, 
such as project evaluations of quality improvement projects. (Helfrich et al., 2010). The PARIHS 
model argues that all of these four sources are equally weighted as sources of evidence. 
Context comprises of sub-elements of organizational culture, leadership and evaluation. 
Culture creates the context for practice, character and feel of the physical environment; effective 
leadership provides clear roles, effective teamwork and effective organizational structures; and 
evaluation refers to the types of measurement tools and methods for reporting used by the 
organization (Stetler et. al., 2011). 
Application of EBP Model to EBP Project 
The PARIHS EBP model was ideal because it allowed for the translation of theoretical 
knowledge to practice. By understanding the context of the organization, the DNP student 
facilitator was able to determine the most appropriate method to improve practice at the pain 
clinic. The need for the EBP project was ascertained following discussion with the administrator. 
Education was provided to prescribing providers and supportive staff. A champion medical 
assistant was identified to help with the roll out process, data collection and the education of 
other supportive staff with regards to project goals and outcomes. The DNP facilitator also 
discussed components of the electronic medical record (EMR) with the information technology 
staff, and then created the auto text component specific the quarterly triad tool which prompted 
allowed providers to download all the components of the tool within their clinic visit notes within 
seconds. The auto-text component was also used by the staff at the clinic routinely for 
documentation of other components of care. 
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Strengths and Limitations of EBP Model for EBP Project 
The main strength of the EBP model was the fact that the DNP student facilitator was 
also part of the staff at this clinic with established credibility and authority within the 
organization. Secondly, the DNP student understood the EMR which allowed for easy 
navigation, creation and inclusion of the QTT within the charting system. Given that the project 
did not require any funding or additional staffing hours for implementation, it was well accepted 
by both leadership and staff. The model provided preliminary measure of evidence and context, 
and the use of the most appropriate methods of implementation. The limitation of the framework 
was the inability to assess how each of the elements of the framework impacted the 
implementation of the project as it appeared that facilitation took precedence over evidence and 
context. 
Literature Search 
Sources Examined for Relevant Evidence 
An extensive literature search was conducted using multiple databases including 
CINAHL, Cochrane Library, Science Direct, ProQuest, and MEDLINE (EBSCO host). Additional 
literature was also obtained from a hand search and citation chasing. The purpose of the 
literature review was to uncover evidence that supported the most effective approach of 
evaluating at risk patients for CBU. Results were compiled and the best interventions were 
included in the design of the evidence-based project (EBP). Interventions which included a 
routine review of urine drug screens (UDS) and prescription drug monitoring programs (PDMP) 
to assess for concurrent benzodiazepine use (CBU), were used to create the quarterly triad tool 
(QTT), which was implemented in the project.  
Search terms included Opioid* AND Prescriber OR Prescription AND PDMP OR 
“Prescription Drug Monitoring Program” OR Urine Drug Screen OR Benzodiazepines and 
chronic pain. The numbers of results found in each database can be found in Table 2.1. 
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 Inclusion criteria for the literature search encompassed publications from 2012 to 
present to accommodate the dynamic nature of this project and include the most up to date 
information. The publications had to be in English language, scholarly or academic journals, and 
peer-reviewed journals covering outpatient adult populations. Inpatient, pediatric, studies of 
dental providers were excluded. Articles that did not address concurrent benzodiazepine use 
were also excluded. 
The initial literature search yielded 104 relevant articles, of which 35 were duplicates and 
32 did not fit the inclusion criteria. A review of the remaining 37 abstracts resulted in seven 
articles being deemed worthy of further review based on inclusion criteria. Four of the seven 
articles that were selected for review were from a hand search and one was obtained from 
citation chasing. After reviewing a full text of the seven articles, the DNP student determined 
that all seven met both inclusion and exclusion criteria based on the level and the quality of 
evidence. Results are as listed below (Table 2.1.) 
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Table 2.1  
 
Literature Search  
 
Database  Articles  
Found 
Duplicates  Abstracts  
Read 
Applicable 
Articles  
Cochrane  12 
 
0 12 0 
CINAHL 34 
 
0 14 1 
ProQuest 40 
 
25 0 0 
Science 
Direct 
10 
 
6 4 1 
Medline 
EBSCO 
Host 
8 4 4 0 
Hand 
Search 
5 0 3 5 
Total  109 
 
35 37 7 
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Table 2.2  
 
Evidence Table  
 
 
CITATION 
 
DESIGN/ 
LEVEL/ 
QUALITY 
RATING   
 
SETTING/SAMPLE/ 
TARGET GROUP  
 
INTERVENTION/ 
RECOMMENDATIONS  
 
OUTCOMES/ 
MEASURES 
 
FINDINGS  
CENTERS 
FOR DISEASE 
CONTROL 
AND 
PREVENTION 
(2016) 
 
Clinical 
practice 
guideline 
Level IV 
High 
quality  
Primary care 
clinicians who are 
prescribing opioids 
for chronic pain 
outside active 
cancer treatment, 
palliative care, and 
end of life care 
Recommends routine 
assessment for patient risk and 
addressing harms of opioid use 
through (a) review of PDMP 
data to identify opioid dosages 
or dangerous combinations 
linked to risk for overdose, (b)  
urine drug testing before 
starting opioid therapy and then 
at least annually to assess for 
prescribed medications, other 
controlled prescribed drugs and 
illicit drugs, (c) avoidance of 
concurrent prescribing of 
benzodiazepines and opioids  
Guideline is intended 
to improve 
communication 
between clinicians 
and patients about 
risks and benefits of 
opioid therapy for 
chronic pain, improve 
safety and 
effectiveness of pain 
treatment and reduce 
the risks associated 
with long-term opioid 
therapy, including 
opioid use disorder, 
overdose and death 
 
DOBSCHA, S. 
K. (2013) 
Expert 
opinion 
Level V 
High 
quality 
Clinicians caring for 
patients impacted by 
CBU 
Recommends moving beyond 
“just say no” where providers 
should outline an “exit strategy 
for the discontinuation of 
concurrent benzodiazepine-
opioid use 
Exploring follow up 
plans for patients on 
CBU while reducing 
anxiety and limiting 
recurrent use: 
communication with 
patients; gradual dose 
reductions; medication 
substitute; CBT; 
clinician education and 
feedback; monitoring; 
and system support.  
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GEORGE, 
2018 
Expert 
opinion  
Level V 
Good 
quality  
 
Patients on opioid 
and benzodiazepines 
as evaluated from 
urine drug screens  
Clinicians need to be aware of 
their patients are taking are 
using potentially dangerous 
combinations of drugs: 
benzodiazepines and opioids. 
State based PDMP are limited 
to prescribed drugs; therefore, 
a more effective detection of 
drug use is achieved by 
supplementing the prescribed 
database information with UDS  
Non-prescribed 
CBU cannot be 
determined by 
PDMP alone. 
Urine drug 
screens of patients 
on opioids were 
reviewed, 68.2% 
of specimens 
tested positive for 
opioids, 20.6% of 
specimens tested 
positive for CBU. 
Of these patients, 
36% had been 
prescribed both 
drug classes and 
64% had at least 
one non-
prescribed drug 
GUDIN, J. A., 
MOGALI, S., 
JONES, J. D., 
& COMER, S. 
D. (2013) 
Expert 
opinion 
Level V 
High Quality 
Patients on CBU  Chronic pain patients 
taking opioids and 
benzodiazepines 
concurrently require 
routine monitoring for 
aberrant drug 
behaviors, treatment 
compliance, 
documentation of 
medical necessity and 
the adjustment of 
treatment to clinical 
changes are essential. 
Patients receiving COT 
should periodically 
undergo urine drug 
testing to confirm 
adherence to the 
treatment plan 
 
Routine 
monitoring for 
compliance and 
aberrant 
behavior to 
mitigate risks 
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HAWKINS, E. 
J., MALTE, 
C.A., 
GROSSBARD, 
J. R. (2015) 
Retrospective 
research 
study 
Level III 
Good quality 
Patients with post-
traumatic stress 
disorder at a veteran’s 
affairs clinic on CBU 
Concurrent use was 
identified as periods of 
overlapping opioid and 
benzodiazepines 
prescriptions for 90 
days or more 
consecutively. Gender-
specific logistic 
regressions estimated 
long-term concurrent 
use of these 
medications and tested 
for linear trends over 9 
years 
The use of 
comprehensive 
strategies to 
identify and 
monitor patients 
on chronic 
opioid and 
benzodiazepines 
for adverse 
outcomes 
Despite known risks 
associated with 
concurrent opioid and 
benzodiazepine use, the 
adjusted prevalence 
rose significantly among 
these patients over a 9-
year period. This 
common use suggests 
that comprehensive 
strategies are needed to 
identify and monitor 
patients as risk for 
adverse outcomes 
MCCLURE, F. 
L., NILES, J. 
K., KAUFMAN, 
H. W., & 
GUDIN, J. 
(2017) 
Qualitative 
Level III 
High quality  
Patients on concurrent 
opioid-benzodiazepine 
use identified from 
urine specimens that 
tested positive for both 
medications  
The urine specimens 
that were prescribed 
either an opioid or a 
benzodiazepine were 
tested for both 
medications  
A high 
prevalence of 
concurrent use 
was noted, 
particularly non-
prescribed use. 
This suggested 
the need for 
more effective 
clinician 
assessment and 
intervention  
Results supported the 
CDC guideline that drug 
testing should occur 
before and periodically 
throughout opioid use 
and suggest that this 
testing should be 
extended to patients 
prescribed 
benzodiazepines as well  
OREGON 
HEALTH 
AUTHORITY 
PUBLIC 
HEALTH 
DIVISION. 
(2016) 
Clinical 
Practice 
guideline 
Level IV 
High quality 
All clinicians 
prescribing opioids in 
Oregon 
Task force endorsed 
CDC guidelines as 
stated above 
Same as those 
recommended by the 
CDC since the adopted 
the CDC guidelines 
To provide 
additional clarity 
to the CDC 
guideline and to 
address Oregon 
specific issues 
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Levels of Evidence 
A total of seven sources of evidence were deemed worthy of inclusion into the literature 
supporting this EBP, which included two descriptive studies, three expert opinions, and two 
clinical guidelines. After obtaining permission for use, these sources were appraised using the 
Johns Hopkins Research Evidence Based Practice Appraisal tool. Evidence was ranked from 
level I through level V, with level one being representative of the highest level of evidence and 
level V the lowest (Dearholt & Dang 2014). The literature search did not yield any randomized 
control studies, experimental or quasi-experimental studies, which would have been considered 
level I and II levels of evidence. This was attributed to the likelihood of the ethical nature of 
selective screening for patients who were on concurrent benzodiazepine-opioid use; providers 
could not compromise patient safety by screening a specific set of patients over the others. It 
however yielded two level III research studies; (Hawkins et al., 2015; McClure, Niles, Kaufman, 
& Gudin, 2017), two level IV clinical practice guidelines from the CDC and Oregon Chronic 
Opioid Prescribing guidelines, and three level V expert opinions (Dobscha, 2013; George, 2018;  
Gudin, Mogali, Jones, & Comer, 2013). 
Appraisal of Relevant Evidence 
Construction of Evidence-based Practice 
Level III Evidence  
Hawkins et al. (2015) examined the trends in annual prevalence of long-term concurrent 
opioid and benzodiazepine use among patients with posttraumatic stress disorder (PTSD) and 
prevalence of high-risk conditions in concurrent users of these medications. The researchers 
conducted a retrospective review of pharmacy records of patients at a Veteran’s Affairs clinic. 
Concurrent use was defined as overlapping opioid and benzodiazepine prescriptions for at least 
90 consecutive days. Gender-specific logistic regressions estimated long-term concurrent use of 
these medications and tested for linear trends over nine years. The researchers found that, 
despite known risks associated with prescribing opioids and benzodiazepines concurrently, the 
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prevalence of long-term concurrent use rose significantly among men and women with PTSD 
over a 9-year period. The researchers concluded that comprehensive strategies were needed to 
identify and monitor patients at increased risk for adverse outcomes. 
After permission for use was granted (see Appendix A), this article was evaluated using 
the Johns Hopkins Nursing Evidence-Based Practice Research Evidence Appraisal Tool and 
found to be of good quality. The study supported the necessity for comprehensive monitoring 
strategies to reduce CBU use, which was the premise behind the creation of the QTT.  
McClure, Niles, Kaufman, and Gudin, (2017), analyzed CBU prescription patterns in the 
context of urine drug testing results and found CBU in 25% of opioid prescribed patients. In 52% 
of those with evidence of CBU, one drug class was prescribed, while the other was non-
prescribed. Nearly one of five specimens testing positive for prescribed opioids also tested 
positive for non-prescribed benzodiazepines. While more than 15% of those who were 
prescribed benzodiazepines also had evidence of non-prescribed opioid use. The researchers 
concluded that the extent of CBU and opioids, particularly the non-prescribed use, reflected the 
need for more effective clinician assessment and intervention. The researchers’ findings 
supported the CDC guideline that drug testing should occur before and periodically throughout 
opioid use and suggested that this testing should be extended to patients prescribed 
benzodiazepines as well.  
This research article was also found to be of high quality. The evidence supported the 
use of urine drug screens (which are a component of the QTT) to evaluate for prescribed and 
non-prescribed CBU periodically throughout opioid use.  
Level IV Evidence  
Clinical practice guideline from the CDC recommend for clinicians to review the history 
of controlled substance prescription using the states prescription drug monitoring program 
(PDMP) data to determine whether the patient is receiving opioid dosages or dangerous 
combinations that put the patient at risk for overdose. The guideline recommends for clinicians 
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to use PDMP at the initiation of opioid therapy and then periodically during opioid therapy 
ranging from every prescription to every 3 months. The guidelines also recommend the routine 
assessment of urine drug screens to assess for prescribed medications as well as other 
controlled prescription drugs and illicit drugs. Finally, the guidelines recommend the avoidance 
of concomitant prescribing of benzodiazepines and opioids whenever possible.  
According to the John Hopkins Nursing Evidence-Based Practice Research Evidence 
Appraisal Tool, this research article was of high quality. The QTT encompasses all the 
recommendations of the CDC guideline in one routine assessment. 
Clinical guideline from the American Academy of Pain Medicine and Oregon Chronic 
Opioid Prescribing guidelines reinforce the avoidance of concurrent benzodiazepine-opioid 
prescribing, routine use of PDMP and periodic assessment of urine drug screens. Both sources 
of evidence were rated as high-quality evidence per John Hopkins Nursing Evidence-Based 
Practice Research Evidence Appraisal Tool  
Level V evidence by alphabetical order  
Steven K. Dobscha, MD is a Doctor at the Center to Improve Veteran Involvement in 
Care (CIVIC) at the Veterans Affairs Medical Center in Portland Oregon. He has 31 years of 
experience. His specialties include; Psychosomatic Medicine, Clinical Informatics, Psychiatry 
and Neurology. His body of work entails approaches to integrating psychiatric and primary 
medical care and managing chronic conditions including chronic pain in primary care. According 
to Dobscha (2013), multiple studies have shown that patient with psychiatric conditions are 
more likely to be prescribed opioids than patients without psychiatric conditions. He noted that 
psychiatric disorders (i.e., anxiety and post-traumatic stress disorders) are strongly associated 
with opioid prescriptions. He noted that the increase in CBU prescription patterns could be 
attributed the fact that chronic pain and anxiety are comorbid. He argues that several 
interventions have been shown to be effective in increasing rates of benzodiazepine 
discontinuation while reducing anxiety and limiting recurrence of use, he listed follow up 
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examples like writing letters to patients explaining necessity for discontinuation, use of 
structured gradual dose reduction programs, prescription of substitute medication and 
psychological treatment considerations like cognitive behavioral therapy. He also suggested that 
interventions that are likely to change clinician behavior and result in improved patient outcomes 
should involve: clinician education, feedback and monitoring, and system support. These 
interventions go beyond the guidelines.  
According to the John Hopkins Nursing Evidence-Based Practice Research Evidence 
Appraisal Tool, this research article was of high quality. The first step of the QTT would be 
identification of CBU through screening. Then, providers can undertake individualized or 
system-wide follow up plans to reduce CBU. Like the recommendation by Dobscha the QTT 
involves clinician education of the indication and benefit of using the QTT, its inclusion in the 
EMR allows for feedback and monitoring of identified patients and its ease of use through the 
recommended auto-text quick chart option allows for an easy incorporation into routine 
documentation  
Jeffrey Gudin, MD, is a director of pain and palliative care at Englewood Hospital AND 
Medical Center in New Jersey. He is board certified in pain medicine, anesthesiology, addiction 
medicine and hospice/palliative medicine. Dr. Gudin’s clinical and research focus includes post-
operative pain management, opioid abuse and potential solutions, and increasing clinician 
awareness of pain assessment and risk management. In a published article that serves as an 
expert opinion. Gudin et. al., (2013) opined that in order to improve patient outcomes for chronic 
pain patients taking opioids and benzodiazepines concurrently, routine monitoring for aberrant 
drug behaviors, treatment compliance, documentation of medical necessity and the adjustment 
of treatment to clinical changes are essential. They stated that regardless of the risk of risk or 
known aberrant drug-related behaviors, patients receiving COT should periodically undergo 
urine drug testing to confirm adherence to the treatment plan. 
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According to the John Hopkins Nursing Evidence-Based Practice Research Evidence 
Appraisal Tool, this research article was of high quality, it supported the periodic use of urine 
drug screens to confirm adherence to the treatment plan.  
Judy George is a freelance journalist and a contributing writer for MedPage today, an 
online clinical website which covers both clinical and policy issues that impact healthcare 
professionals. Her article is a review of a poster presented at the pain week by L. McClure and 
colleges. The data summarized from the poster indicated that among a selected sample of 
patients whose drug test indicated concurrent benzodiazepine and opioid use, 64% had at least 
one benzodiazepine or opioid that was not prescribed. These findings supported the use of a 
UDS in addition to PDMP to evaluate for CBU. 
According to the John Hopkins Nursing Evidence-Based Practice Research Evidence 
Appraisal Tool, this research article was of good quality, it supported the additional use of a 
urine drug screen in addition to PDMP review to evaluate for non-prescribed use.  
Synthesis of Critically Appraised Literature 
A major theme which was identified in the literature review was the formidable challenge 
faced by clinicians of concurrent benzodiazepine-opioid use among patients on chronic opioid 
therapy (CDC, 2016; Dobscha, 2013; George, 2018; Gudin, Mogali, Jones, & Comer, 2013; 
McClure, Niles, Kaufman, & Gudin, 2017; Oregon Health Authority Public Health Division, 
2016). The majority of evidence for this EBP project stemmed from expert opinion and clinical 
practice guidelines. These experts identified the need for screening (Dobscha, 2013; Hawkins et 
al., 2013) and intervening (CDC, 2016; George, 2018; Gudin, Mogali, Jones, & Comer, 2013; 
McClure, Niles, Kaufman, & Gudin, 2017; Oregon Health Authority Public Health Division, 2016) 
to address CBU. Some of the evidence reviewed focused on the use of both UDS and PDMP 
(CDC, 2016; George, 2018; Hawkins et al., 2013; and Oregon Chronic Opioid Prescribing 
guidelines;) while others focused on the use of UDS independently (Gudin, Mogali, Jones, & 
Comer, 2013; McClure, Niles, Kaufman, & Gudin, 2017).  Both CDC and Oregon guidelines 
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recommended the review of PDMP at the initiation of opioid therapy and then periodically 
throughout opiate therapy. CDC and Oregon guidelines recommended screening every 3 
months (CDC, 2016; Oregon Health Authority Public Health Division, 2016) 
Best Practice Model Recommendation 
Consistent with the PARIHS model, the EBP project was facilitated by the utilization of 
appraised literature (evidence), to promote a recommended practice change at the pain clinic 
(context) the through the use of the QTT (mechanism). The DNP student presented the 
evidence to the providers at the facility, and it was determined that the best practice 
recommendations were applicable to the project with regards to the creation and utility of the 
QTT for risk assessment and mitigation. The evidence review highlighted best practice 
recommendations that were needed to answer the PICOT question: Among pain management 
providers (P), does the use of a standardized quarterly triad tool (QTT) consisting of PDMP, 
UDS, and medication reconciliation for CBU (I), compared to the current practice of PDMP or 
UDS only (C), increase the monitoring of CBU and providers initiation of a benzodiazepine 
specific follow up plan (O) over a 90-day period (T)?  
How the Best Practice Model Will Answer the Clinical Question 
Evidence from the literature synthesis provided the foundation for the creation of the 
quarterly triad tool (QTT). The operational plan entailed provider and support staff education on 
the utility and necessity of the QTT. It was agreed upon by the DNP student facilitator and 
clinical leadership that the QTT, comprising of; an evaluation of the prescription drug monitoring 
program, urine drug screen and concurrent benzodiazepine use assessment from the 
medication reconciliation would be uploaded in patients’ electronic monitoring record. This 
would be done in a quick chart format also known as auto text. Providers would then evaluate 
patients on chronic opioids seen monthly at each of their third visit for concurrent opioid and 
benzodiazepine use using all the three parameters. The DNP student facilitator was selected as 
the clinical champion for the providers and the lead medical assistant was identified as the 
CONCURRENT BENZODIAZEPINE-OPIOID SCREENING                                                      24 
 
 
clinical champion for the supportive staff. A power point presentation created by the DNP 
student was used for one-on-one education session with the providers and the support staff. 
The PARIHS model incorporates evidence, context and mechanism by which change is 
facilitated as key variables in the translation of research into practice. The context was ideal 
given that providers saw a large volume of patients with chronic pain on opioids who were seen 
routinely (monthly), for follow up visits. It was therefore imperative to ensure that chronic opioid 
prescribing was done within the appropriate safety guidelines. The research evidence, both 
contextual and theoretical as discussed in chapters one and two was strong enough to justify 
the necessity for the project implementation with regard to risk, impact and recommendations 
for intervention. Additionally, the DNP student and the facility leadership engaged in careful 
planning of the intervention and its components (use of QTT), staff involvement and the 
incorporation of the intervention into charting and routine practice. Finally, an audit and 
management of project outcome would be attained through the data collection process. 
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CHAPTER 3 
IMPLEMENTATION OF PRACTICE CHANGE  
The CDC has recommended avoidance of concurrent prescribing of opioids and 
benzodiazepines as a risk mitigation strategy in patients on chronic opioid therapy (CDC, 2016). 
However, evidence has noted that 30% to 40% of patients prescribed long-term opioids are also 
prescribed benzodiazepines (Dobscha, 2013). Even more concerning is the statistic that 65.8 % 
of patients prescribed long-term opioids are taking benzodiazepines from non-prescription 
sources (McClure et al., 2017). Concurrent use of benzodiazepines is likely to put patients at 
greater risk for hospitalization and potentially fatal overdose (CDC, 2016) Practices often use 
PDMP regularly to evaluate for concurrent use of prescribed medications which may increase 
risks associated with COT, but this strategy fails to capture and address those who may be 
using benzodiazepines not obtained via a prescription. Therefore, state and national guidelines 
now recommend the routine use of PDMP and UDS to evaluate risk in patients on COT. 
This chapter will describe the methods used to answer the following PICOT question: 
Among pain management providers in an outpatient clinic, does the use of a standardized 
quarterly triad tool with concurrent benzodiazepine use (CBU) assessment, promote provider 
adherence to the monitoring and decrease of CBU, compared to the current practice of not 
using the quarterly triad tool, within a 90-day period? A single group pre- and post-intervention 
analysis was used to address the purpose of this project. In this section, details about the 
participants, setting, planning, evidence implementation, anticipated outcomes, and human 
rights protection considerations planned for the project will be described.  
Participants and Setting 
The project was initiated in a specialty pain clinic setting, where prescribers were vested 
in a multi-disciplinary team approach in improving patient safety outcomes, with CBU being one 
of the key markers, with regards to chronic opioid prescribing. One of the unique features of the 
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setting for this EBP project is that both administrators and clinical staff (key stakeholders) were 
proactive about preventing CBU within the patient population. Both groups of stakeholders had 
identified safe opioid prescribing, including the avoidance of CBU, as a high priority initiative to 
combat the local opioid epidemic. Strategies that were in use at the time this project was 
implemented included (a) adoption of a shared value system in which CBU was discouraged, 
(b) avoidance of prescribing benzodiazepines to patients on long-term opioid therapy, (c) 
initiation of an opioid weaning goal of less than 90 morphine milligram equivalents (MME), (d) 
the opportunity for patients to prioritize either their pain or their anxiety as their treatment goal, 
and (e) the implementation of a therapeutic interchange program, which entails changing from a 
benzodiazepine to a non-benzodiazepine for anxiety management.  
The provider participants in this EBP project included all prescribers of chronic opioids 
who completed routine quarterly visits at the pain clinic in the Midwestern United States. The 
clinic had been in existence for past 17 years. Patients were self-referred or referred by PCPs 
for management of chronic pain. The make-up of provider staffing on a typical Wednesday (the 
day selected to obtain baseline data) included three physicians, two physician assistants (PAs), 
and a nurse practitioner (NP). Of the three physicians, one was relatively new to the clinic, 
having been at the clinic since December of 2018, but also having more than three years of 
experience in pain management. The other two physicians both had more than 10 years of 
experience in chronic pain management and had been at the clinic for more than five years. 
One of the two PAs had more than 10 years of PA experience and had been at the clinic for 
more than five years, and the other had three years of experience and had been at the clinic for 
three years.  The NP, the DNP student facilitator, had worked at the pain management clinic for 
more than a year.  Apart from the NP, who worked part time (3 days a week), all the other 
providers were full time. Each provider had a separate panel of patients whom they cared for 
routinely and saw an average of 18 to 25 patients on a Wednesday.  
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Other key stakeholders and project participants included all medical assistants (MAs) 
who assisted in the patients’ “rooming process” as well as the compliance registered nurse (RN) 
who selected patients randomly for the evaluation of quarterly baseline data. The clinic 
administrator was the DNP student’s project facilitator at the site.  
Patients, of all providers, who were being seen for their quarterly visit were the target of 
the change in provider behavior. Because the project design included a systematic change 
within the entire clinic, patients seen by the DNP student were included in the project. The 
inclusion criteria for patients was all adult patients over the age of 18 on long-term opioids under 
the supervision of clinician, who were seen for quarterly visits on Wednesdays. There were no 
additional exclusion criteria for providers or patient participants.  
Pre-implementation Data   
The clinic providers were already screening for illicit drugs like cocaine, heroin, 
methamphetamines, and other opioids not otherwise prescribed at the pain clinic) by 
discretionary random UDS. Some incidental CBU through random UDSs and patients’ reports 
during medication reconciliation patterns were also identified.   
The pre-implementation data was evaluated in August of 2018. The clinic support staff 
provided data on all quarterly visits done on Wednesdays for a 12-week period. Total patient 
numbers of quarterly assessments ranged from 8 to 20 each Wednesday. Pooled total data 
from four Wednesdays of quarterly visits yielded a sample size of 52.  Twenty of these patients 
(38%) were found to have been on both benzodiazepines and opioids. 5%) had patient specific 
follow up plans documented within the electronic charting. Education for patients on CBU also 
included risks associated with other non-benzodiazepine medications (e.g., muscle relaxants, 
sedative hypnotics, and alcohol) which presented the risk of central nervous system depression  
Although providers had documented a review of PDMP, of the 52 reviewed charts, none of the 
providers had specifically documented that they specifically screened for CBU. In 3 of 20 charts 
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where CBU was identified, opioid therapy wean was initiated. In the remaining 17 charts, no 
interventions were documented. 
Outcomes 
The primary outcome of the EBP project was the standardization and intensification of 
provider adherence with CBU screening. Compliance was defined as a ratio of the number of 
times in which providers used the QTT to the number of times CBU was identified. Other 
additional goals included the number of times CBU was identified and the number of times risk 
education was performed and finally the number of times CBU was identified and the number of 
times follow up education was initiated. For the purpose of this project, QTT should have been 
used by each participant at every quarterly visit to be in alignment with the CDC 
recommendations (CDC, 2017). Data to calculate this compliance ratio was retrieved from 
patients’ medical records.  
It was anticipated that as an added benefit, use of the QTT would result in 
standardization of provider documentation with its inclusion in the electronic medical record 
(EMR). The inclusion in the EMR would also simplify the screening process through the use of 
the auto text application which copied and pasted the tool to the patients’ visit note. This 
process was streamlined to minimize effort and improve compliance. 
Intervention 
In the pre-implementation phase, the DNP student facilitator evaluated the clinic for 
project preparedness by establishing provider and staff buy-in, consistent with Kotter’s change 
model. Then, the project facilitator collected data about the provider compliance with the use of 
the QTT inclusive of all three components: prescription drug monitoring program, urine drug 
screen, and a review of the medication reconciliation. CBU identification as well as provider-
patient education patterns and follow up planning if CBU was identified, was completed using a 
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data collection tool (Appendix B). The DNP student facilitator also procured educational 
materials and developed a face-to-face education plan for the prescribing providers. 
Following approval by the Institutional Review Board at Valparaiso University, 
implementation of the project began in September 2018. Implementation included a formal 30-
minute face-to-face education sessions from September 1st-3rd and the identification and 
appointment of a clinical champion. Education was delivered using a face-to-face approach 
scheduled at convenient times for each provider over a 3-week period of time. Each prescribing 
provider was educated separately. Education included the following topics: best practice for 
chronic opioid prescribing, need for elimination of concurrent benzodiazepine use through 
individualized follow up plans for patients and utility of the quarterly tried tool. Lecture slides and 
the CDC Guideline for Prescribing Opioids for Chronic Pain (Appendix C) were provided to clinic 
staff. During this phase, the quarterly triad tool (Appendix E) was implemented. The triad tool 
consisted of a quarterly PDMP and UDS with specific instructions to monitor both for evidence 
of CBU. Furthermore, the combined approach using the PDMP and UDS would assist providers 
in identifying both prescribed and unprescribed or illicit benzodiazepine use. The PDMP would 
identify prescribed medications while the UDS would detect non-prescribed medications or illicit 
drug use. Providers were instructed to educate patients on risks and discuss a plan for 
discontinuation of concurrent opioid and benzodiazepine use if CBU was identified.  
Planning 
In the pre-implementation phase, the DNP student facilitator evaluated the clinic for 
project preparedness by establishing provider and staff buy-in, consistent with Kotter’s change 
model. Then, the project facilitator collected data about the provider compliance with the use of 
the QTT inclusive of all three components: prescription drug monitoring program, urine drug 
screen, and a review of the medication reconciliation. CBU identification as well as provider-
patient education patterns and follow up planning if CBU was identified, was completed using a 
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data collection tool (Appendix B). The DNP student facilitator also procured educational 
materials and developed a face-to-face education plan for the prescribing providers. 
Following approval by the Institutional Review Board at Valparaiso University, 
implementation of the project began in September 2018. Implementation included a formal 30-
minute face-to-face education session from September 1st-3rd and the identification and 
appointment of a clinical champion. Education was delivered using a face-to-face approach 
scheduled at convenient times for each provider over a 3-week period of time. Each prescribing 
provider was educated separately. Education included the following topics: best practice for 
chronic opioid prescribing, need for elimination of concurrent benzodiazepine use through 
individualized follow up plans for patients and utility of the quarterly tried tool. Lecture slides and 
the CDC Guideline for Prescribing Opioids for Chronic Pain (Appendix C) were provided to clinic 
staff. During this phase, the quarterly triad tool (Appendix D) was implemented. The triad tool 
consisted of a quarterly PDMP and UDS with specific instructions to monitor both for evidence 
of CBU. Furthermore, the combined approach using the PDMP and UDS would assist providers 
in identifying both prescribed and unprescribed or illicit benzodiazepine use. The PDMP would 
identify prescribed medications while the UDS would detect non-prescribed medications or illicit 
drug use. Providers were instructed to educate patients on risks and discuss a plan for 
discontinuation of concurrent opioid and benzodiazepine use if CBU was identified. 
Data 
This EBP project measured provider compliance with monitoring CBU. Data was 
measured as a ratio, which allowed for compliance to be analyzed as a continuous variable. It 
also measured compliance/adherence rates per provider. The end data compared the number 
of times that provider used QTT to screen for CBU, and if CBU was identified, further steps 
were taken to determine if (a) risk education was provided and (b) an individualized plan of care 
was initiated for the patient.  
Measures 
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Chi square analyses were used to evaluate provider adherence rates. Descriptive 
statistics were used to document information pertaining to risk education and follow up plans for 
patients who screened positive for concurrent benzodiazepine-opioid use.   
Collection 
Data collection was initiated one month following the launch of the intervention. The 
compliance registered nurse identified patients who would be coming in for the 3rd month visit of 
the year also known as the quarterly visit each Wednesday. The MA champion printed out a 
quarterly visit summary, designating each patient to their assigned provider on Tuesday 
evening. Random sampling of patients was completed until at least 20 patients identified to be 
on CBU were seen. Data evaluating provider adherence to screening using the quarterly triad 
tool was obtained within 12-week timeframe between October 2018 and December 2018. The 
DNP project facilitator collected data using a chart audit process with a standardized data 
collection form (Appendix E). Specific evaluative data collected included (a) if the QTT was 
used, (b) if CBU was identified, (c) whether patient risk education was documented if CBU was 
identified, and (d) if an individualized follow up plan was identified.  
Management and Analysis 
The DNP student collected the data through a chart audit process and recorded it in a 
Microsoft Excel spreadsheet. IntellectusStatisticsTM software was used for data analysis. To 
analyze the main outcome of this project, the use of the QTT with all the three components 
(UDS, PDMP and medication reconciliation to screen for CBU) was coded as “QTT yes” or 
“QTT no” for each provider. Screening for CBU was coded as “CBU yes “or “CBU no”. Risk 
education documentation was coded as “RE yes” or “RE no” and follow up education was coded 
as “FU yes” or “FU no”. Compliance with these components was calculated as percentage. 
Descriptive statistics were used to determine if providers who used the quarterly triad 
tool were effective at educating patients on risks for CBU and initiating follow up planning, a chi-
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square analysis was performed to compare the pre and post QTT implementation follow up 
planning.  
Protection of Human Subjects 
The DNP student completed human rights training from the National Institutes of Health 
(NIH) in April 2018 (Appendix F). The student then received the Institutional Review Board (IRB) 
clearance from Valparaiso University in September 2018. Permission to use the clinical site was 
provided by the administrator. The project was considered exempt for the institutional review 
board because the information collected was de-identified and there was no patient interaction 
or treatment that would have involved physical procedures by which data are gathered (e.g., 
venipuncture) and manipulations of the subject or the subject's environment that would be 
performed for research purposes, therefore patient consents were not necessitated.  
The DNP student had access to the EMR through authorization from her active 
employment status at the clinic, and the initial audits were conducted in a closed office without 
other staff members to ensure data protection. The DNP student gathered the data from the 
printed quarterly visit summary in her office alone, deidentified, coded and recorded it on the 
excel worksheet on the DNP student’s lap top which was password locked. This spreadsheet 
was stored on the DNP student facilitator’s secure laptop, and no patient identifying information 
was used or stored in compliance with HIPAA. The summary with patient identifying information 
was stored in a designated locked cabinet, accessible by key to the MA champion and the DNP 
student. The MA printed the upcoming quarterly visit summaries every Tuesday in her cubby 
and then handed the summaries to the DNP student. For the provider coding, the three 
physician providers were coded with the letter P before their designated number, the PA 
providers were coded with the letter A before their designated number and the NP who was also 
the student facilitator was coded with the letter SF, and because she was the only NP provider, 
there were no numbers assigned to the SF code.   
CONCURRENT BENZODIAZEPINE-OPIOID SCREENING                                                      33 
 
 
The potential for selection bias was minimized given that the DNP facilitator was not 
involved in the random patient selection process. But a plan was designed to evaluate 
adherence to the systematic change with the DNP facilitator’s data both included and excluded 
from final analyses. 
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CHAPTER 4 
FINDINGS 
The purpose of this EBP project was to determine the effect of the utility of standardized 
quarterly triad tool on provider adherence to screening for concurrent benzodiazepine-opioid 
use, and its impact on risk education and follow up plans for identified patients. The QTT was 
developed from evidence-based CDC guideline for prescribing opioids for chronic pain, (CDC, 
2017). The PICOT question was: Among pain management providers in an outpatient clinic, 
does the use of a standardized quarterly triad tool with concurrent benzodiazepine use (CBU) 
assessment, promote provider adherence to the monitoring and decrease of CBU, compared to 
the current practice of not using the QTT within a 90-day period? The project was conducted in 
a pain clinic setting in Central Indiana.  
Pre-implementation data was collected from four Wednesdays using a retrospective 
chart review. A retrospective chart review was also used to collect post-implementation data 12 
weeks after the initiation of the project to evaluate the effect of QTT use among six providers.  
Data analyses were conducted using IntellectusStatisticsTM statistical software. Testing was 
performed to answer the following primary question: Does provider education increase the use 
of the QTT to monitor for CBU? Statistical analysis also evaluated the secondary questions: 
Does adherence to QTT increase provider risk education documentation for patients on CBU? 
and Does adherence to QTT increase provider follow up planning documentation for patients on 
CBU? 
Participants 
Participants included six providers who worked on Wednesdays when data was 
collected which comprised of three physicians, two physician assistants (PAs), and a nurse 
practitioner (NP), who led the practice change. All patients on chronic opioid therapy who were 
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at the clinic for their third month visit on Wednesdays per the quarterly visit summary were 
included in the data set. 
Size and Characteristics 
Pre-intervention group characteristics. Summation of data from six providers on four 
Wednesdays of quarterly visits yielded a population of 52.  Twenty of these patients (38%) were 
found to have been on both benzodiazepines and opioids. Of these 20 patients, six were seen 
by physicians, the remaining 14 were seen by advanced practice providers; 11 by one of the 
two PAs and three by the NP. Of the 20 patients on CBU, only 25%, had risk education 
documented and only 5% had patient-specific follow up plans documented within the plan of 
care. The DNP student who was also the project facilitator saw three patients who were 
identified to be on CBU, one of the three patients had risk education (33%) and follow up 
planning (33%) documented. 
Intervention group characteristics. Data was collected from the six providers on 12 
Wednesdays of quarterly visits. One of the six providers did not adopt the QTT. Even with this 
lack of buy-in, a total of 151 of 154 patients (98.05%) were screened.  In 24 of 151 patients 
(15.89%) who were screened, concurrent benzodiazepine use was detected. Of the 24 patients 
who screened positive for CBU, the five remaining providers used the tool (100%) and all the 24 
patients (100%) also had risk education documented. Of the 24 CBU patients, 18 (75%) had a 
follow up plan documented. When follow up information was evaluated with the NP data 
removed (7 CBU patients), a follow up plan was documented in 11 of the remaining 17 patients 
(64.7%). Comparison data are included in Tables 4.1, 4.2, and 4.3. 
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Table 4.1 
 
Post QTT Intervention Evaluation of Practice Change Adoption   
 
Provider QTT 
Yes 
QTT 
No 
CBU 
Yes 
CBU 
No 
Risk Ed 
Yes 
Risk Ed 
No 
Follow 
Yes 
Follow 
No  
Ph 1 0 3 0 0 0 0 0 0 
Ph 2  12 0 2 10 2 0 1 1 
Ph 3 12 0 1 11 1 0 1 0 
APP 1 36 0 7 29 7 0 2 5 
APP 2 48 0 7 41 7 0 7 0 
APP 3 43 0 7 36 7 0 7 0 
Total with 
APP 3  
151 3 24 127 24 ---- 18 6 
Total with 
APP 3 
removed 
108 3 17 91 17 ---- 11 6 
 
 
 
Table 4.2  
 
Provider Risk Education and Follow Up Post QTT Adoption 
 
Provider % Risk education  % Follow up 
Ph2 100% 50% 
Ph3 100% 100% 
APP1 100% 27% 
APP2 100% 100% 
APP3 100% 100% 
Total with APP3 100% 75% 
Total with APP3 removed  100% 65% 
 
 
 
 
Table 4.3  
 
Comparison of Pre-Intervention and Post-Intervention Risk Education and Follow up Plan 
Documentation 
 
Risk Education                Follow Up Plan Documentation   
Pre-Intervention    Post-Intervention  Analyses      Pre-Intervention   Post-Intervention   Analyses 
(n = 20)         (n = 24)                       (n = 20)     (n = 24)                     
5 [25%]       24 [100%]        X2 = 10.588       3 [15%]   18 [75%]           X2 = 8.235         
                                                       p =.001                                                                      p =.004 
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Changes in Outcomes 
Statistical Testing 
Descriptive and inferential statistics were used to compare provider adherence. A Chi-
square test was used to compare risk education and follow up planning for CBU post 
implementation of the use of QTT. Statistical testing was completed using IntellectusStatisticsTM 
software. 
Descriptive Statistics 
Frequencies and percentages were calculated for pre-intervention risk education and 
post-intervention risk education. The most frequently observed category of pre-intervention risk 
education was Y (n = 15, 25%). This statistic reflects that only 25% of patients were provided 
risk education pre-intervention. The most frequently observed category of post-intervention risk 
education was Y (n = 24, 100%), revealing that all patients were provided risk education during 
the intervention period.  
Frequencies and percentages were calculated for pre-intervention follow up and post-
intervention follow up. The most frequently observed category of pre-intervention follow-up was 
N (n = 19, 95%), demonstrating that only 5% of patients (1 of 20) had a follow-up plan 
documented in the EMR. The most frequently observed category of post-intervention follow-up 
was Y (n = 18, 75%), reflecting that three-fourths of CBU patients had a follow-up plan 
documented in their EMR after the practice change was initiated.   
Chi-square Test of Independence 
A Chi-square Test of Independence was conducted to examine whether the differences 
in pre-intervention follow-up (5%) and post intervention follow-up (75%) were statistically 
significant. Results of the Chi-square test was as follows, χ2(1) = 8.24, p = .004; there was a 
statistically significant increase in documentation of a follow-up plan from the pre-intervention to 
post-intervention period. Initial statistical analyses to evaluate the differences in percentage of 
risk education could not be undertaken using Chi-square analyses because post-intervention 
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data were not dichotomous: the only category was Y (yes), with risk education being provided 
for all 24 patients. To provide an estimate of statistical significance in the differences in 
documentation of risk education pre-intervention (25%) to post-intervention (100%), analyses 
were conducted using a statistical violation. Three of the Ys were changed to N so that the post-
intervention percentage was 87.5%, rather than 100%. Conducting the chi-square analysis with 
this statistical violation revealed that the percentage point increase in risk education rates was 
statistically significant χ2(1) = 10.59, p = .001. 
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CHAPTER 5 
DISCUSSION 
This EBP project was designed to answer the PICOT question: Among pain 
management providers in an outpatient clinic, does the use of a standardized quarterly triad tool 
with concurrent benzodiazepine use (CBU) assessment promote provider adherence to the 
monitoring and decrease of CBU, compared to the current practice of not using the QTT, within 
a 90-day period? The project was implemented at a specialty pain management clinic located in 
the Midwest. It was expected that the implementation of a QTT consisting of UDSs, PDMP, and 
medication reconciliation in quarterly patient visits in EMR would promote provider adherence to 
the QTT, resulting in an increase in both patient education and follow up planning.  The 
multifaceted implementation was comprised of (a) provider education, (b) inclusion of the QTT 
in the EMR through the use of a quick auto-text application, (c) use of an MA clinical champion, 
and (d) a team-based approach. This chapter will include an explanation of project findings, 
evaluation of key factors that contributed to the success of this project, project limitations and 
implications for future projects of this nature and conclusive findings. The theoretical framework 
and model used to guide this EBP will be evaluated.  
Explanation of Findings 
The findings of this project reflected those of the supportive literature indicating that tools 
like UDSs and PDMPs should be utilized routinely in addition to medication review and patient 
reports to screen for CBU. Implementation of the multifaceted strategy required the buy in of key 
stakeholders. It readily became apparent that implementation would benefit from the use of a 
clinical champion to facilitate prescriber’s adoption of the behavior change. A medical assistant 
was chosen for this position, and her assistance was invaluable in printing out the quarterly visit 
summaries, PDMP and UDSs without negatively impacting the workflow for the day. Providers 
had been seeing typically 80 to 100 patients per day prior to implementation and that 
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productivity was not reduced during the implementation phase. Providers workday time was not 
expanded as a result of participation in the practice change and they were still able to see the 
same number of patients in the same number of scheduled hours, without staying late or 
skipping lunch.  
The strategy of minimally impacting workflow likely added to the adoption rate of 
providers. Yet, one of the six prescribing providers was a non-adopter of the practice change.  
The three main factors reported for not adopting the change in practice were (a) the task of an 
additional step in otherwise routine documentation, (b) the belief that  behavioral change would 
be temporary and would be dismissed after project completion, and (c) compared to other 
providers, the DNP student spent the shortest amount time educating and reminding this 
provider about the utility of the tool due to time constraints. Although this provider was 
accustomed to the previous practice of patient risk evaluation, it cannot be determined if 
additional education time and reinforcement of practice change would have ultimately changed 
behavior or if an alternative means of education and reinforcement would have enhanced 
adoption of practice change. One could question if the physician would have documented the 
use of the QTT if the change in practice were initiated by a physician colleague or if it were 
mandatory or incentivized.    
Adopting providers noted that the implementation strategies did not negatively impact 
their practice and that the use of the QTT in the EMR made the change in documentation 
seamless. This impression was reflected in the increased documentation of risk education from 
25% of patients pre-intervention to 100% post-intervention. And, although to a lesser extent, the 
use of the EMR led to an increase in adoption rates of documentation of a patient-specific 
follow-up plan from 15% to 75% a statistically significant increase (X2 = 8.235, p =.004). This 
additional step required an individualized approach which took additional time and planning by 
the prescribing providers; thus, it was not surprising that the adoption rates did not reach 100%. 
Still, the adopting providers reported the benefit of being able to quickly document practices that 
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addressed patient safety. An enhanced patient safety is further inferred by the supportive 
evidence of increased risk education and follow up planning documentation from the providers 
who adopted and used the tool. 
The DNP student was a prescribing provider for this project, and it was important to 
evaluate the data with and without her documentation included. It was important to note that 
even the DNP student, project leader, had 100% of follow up plans documented within the 
twelve weeks of the project implementation likely because her awareness of the project was 
heightened. The two providers who did not have 100% follow up education noted that some 
patient specific follow up plans entailed coordination and discussions with providers outside the 
clinic and documentation could not be completed until this was done. Another reason was that 
some patients were discharged a result of recurrent non-prescribed CBU, a violation of their 
opioid contract. 
Evaluation of Applicability of Theoretical and EBP Frameworks 
This project was guided systematically by Kotter’s model of change theoretical 
framework and the PARIHS EBP model. The application is discussed below.  
Theoretical Framework 
The first step of Kotter’s model of change is the creation of the sense of urgency. While 
the DNP student facilitator was able communicate the necessity of adapting the tool 
immediately by discussing national data as outlined in chapter 1 and internal data from the 
clinic, one of six providers did not adopt the tool at the point of initiation. Thee of the five 
remaining providers adopted the tool reluctantly with the expectation that if the project did not 
confer any efficacy to CBU risk education and follow up, they would abort the behavioral change 
after the implementation period and finally, two of the five adopted because they were eager to 
better practice outcomes. The notion that there was a sense of urgency did not appear to be a 
huge driver on attitudes that led to behavioral changes.  
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The second step of Kotter’s model of change was evident in the selection of the medical 
assistant (MA) champion. However, the appointment of the MA champion also created the 
challenge of the engagement and inclusion of the rest of the supportive staff who felt like they 
were not as important to the project. Initially, there was also marked concern from the other MAs 
who felt that their daily routine would be adjusted to accommodate the project. The MA 
champion was instrumental in getting the other supportive staff to rally around the project.  
The third step was the creation of a vision and a realistic implementation strategy for 
bringing the vision to fruition. The DNP student facilitator had 90 days to implement the project 
which guided the timeline. To allow for ease of documentation, the QTT was included in the 
EMR through an auto-text application. However even with the ease in documentation, not all 
providers adopted the QTT.  
Step four of the Kotter model was communicating the vision of going beyond “just 
abiding with the guidelines”. Personal stories of improved patient outcomes were shared by the 
DNP student. There was very little to evaluate on the impact of this step as this was tied in to 
step 3.  
Step five which included staff empowerment for behavioral change and elimination of 
barriers that inhibit successful change was apparent in that this project did not require any 
additional staffing hours or changes in the clinical budget. The use of the auto-text inclusion also 
streamlined the documentation process. However, there was some generalized anxiety among 
staff over additional steps in documentation and data collection to aide in the review of the 2 
additional components of UDSs and PDMP print outs in addition to medication reconciliation to 
evaluate for compliance. There was a variation in practice in that some providers required for 
the assisting MA to review and report identified CBU before they went into the rooms and saw 
that patients, while some providers completed their reviews independently from pre-printed 
UDSs and PDMPs.  
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Step six of Kotter’s theory was outlined by the routine celebration of biweekly successes. 
However, smaller sample groups made it difficult to report impactful change. One of the 
incidental successes was the increased trend in CBU risk education on patients who were not 
on CBU. There was an overall increase in provider-patient risk education.  
Step seven was outlined in the DNP student’s persistence in ensuring that providers 
complied with the use of the QTT through constant reminders. However due to work flow 
variations, the DNP student was unable to constantly reach out to the non-adapting provider to 
impart behavioral change through adherence.  
Step eight which entailed the nourishment of the new culture to make it last became 
apparent as providers not only adapted the tool, but supportive staff continued to print out 
PDMPs and UDSs prior to clinic visits. As a result, patients who were seen on their quarterly 
visits who did not have a UDS within the last three months had UDS orders to evaluate 
compliance. Sustainability of the project will need more time given that the outcomes indicated 
are all within the 90 days of the project implementation phase. 
Overall, while the Kotter theory provided a benchmark that guided the implementation 
process, positions did not always change with the stepwise transitions. Another finding that was 
that some of the steps overlapped each other. 
EBP Framework 
The PARIHS (Promoting Action on Research Implementation in Health Services) 
framework was used in the design and implementation of this EBP project. The main strength of 
the EBP model was the fact that the DNP student facilitator was also part of the staff at this 
clinic with established credibility and authority within the organization. The DNP student 
gathered research evidence from studies and clinical practice guidelines to support project 
implementation. Secondly, the DNP student also had clinical experience as a pain specialist 
working within the clinical context. As a pain provider, the DNP facilitator understood the EMR 
which allowed for easy navigation, creation and inclusion of the QTT within the documentation 
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system. The main limitation of the framework was the inability to assess how each of the 
elements of the framework impacted the implementation of the project, as it appeared that 
facilitation of the project  took precedence over evidence and context given the timelines and 
the reason for the project which was to change clinical outcomes but also to meet the 
educational needs of the DNP facilitator .  
Strengths and Limitations of the EBP Project 
Strengths 
The main strength of the EBP project was the collaboration from leadership providers 
and support staff who embraced the project and its facilitation. Another strength of the EBP 
project was that it did not require any additional funding, staffing or budget changes to support 
its implementation. The DNP student facilitator had strong support from faculty advisors who 
despite the pressures affiliated with project implementation and evidence review, guided the 
DNP facilitator relentlessly through their own personal experiences from past projects. Finally, 
another strength was the current climate of the opioid crisis which automatically created the 
sense of urgency and a need to better practice outcomes in an effort to promote patient safety.  
Limitations 
The main limitation was in the evidence search.  Due to ethical considerations which 
eliminated randomization of screening, the only levels of evidence available were levels IV and 
V which entailed practice guidelines and expert opinions. Another limitation was a very small 
sample group which challenges the generalization of findings. As in the evaluation of patients on 
CBU, the initial data yielded 38.46%, while the post intervention data yielded a 15.58% CBU, 
which indicates that other trends other than the QTT might have already been impacting 
behavioral changes, which makes it difficult to isolate this the outcome of decreased CBU rates 
to the implementation of the project. This could have also been impacted by the fact that data 
was only collected on Wednesdays.  
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Implications for the Future 
Practice 
As clinicians continue to implement practice changes to address patient safety in the 
opioid epidemic climate, this project demonstrates that the role of the Doctor of Nursing Practice 
is instrumental in the evaluation and incorporation of evidence-based research to better patient 
outcomes. The DNP student facilitator was able to chaperone the implementation of evidence 
practice change which in turn imparted behavioral change across a multidisciplinary team of 
healthcare providers.  
Theory 
The Kotter theoretical framework and PARIHS model provided a systematic path for the 
DNP facilitator to navigate the obstacles that arise from transitions. These two theoretical 
frameworks provided a systematic approach which allowed for the incorporation of evidence into 
practice while mitigating resistance associated with the process of change.  
Research 
Future research studies that entail larger sample groups (both provider and patients) and 
longer implementation time frames should be considered before findings can be generalized. 
While the project measured risk education and follow up planning as indicators for CBU 
reduction, further research studies should be done to measure actual CBU reduction as 
evidenced by patient census. 
Education 
The project opened communication lines for well needed provider and patient education 
on effective strategies to mitigate CBU. Follow up planning also incidentally created the need for 
patients who continue to utilize both BZD and opioids due to medical necessity to complete 
consent forms indicating that while they were aware of the existing risks, they opted to continue 
with dual therapies for medical reasons. Other incidental follow-up finding was the inclusion of 
rescue Naloxone in patients who were identified to aide in risk mitigation. 
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Conclusion 
Conclusively, safe chronic opioid prescribing with regards to mitigating and avoiding 
concurrent benzodiazepine and opioid use is necessary in combating the opioid epidemic. This 
EBP project answered the question as posed by the PICOT: Among pain management 
providers in an outpatient clinic, does the use of a standardized quarterly triad tool with 
concurrent benzodiazepine use (CBU) assessment, promote provider adherence to the 
monitoring and decrease of CBU, compared to the current practice of not using the QTT within a 
90-day period? The post intervention outcome was yes. This project also demonstrated that the 
role of the DNP is crucial in the opioid crisis climate to aide in the research evaluation and 
implementation to promote safe opioid prescribing patterns 
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ACRONYM LIST 
AGPCNP: Adult Geriatric Primary Care Nurse Practitioner  
BZD: Benzodiazepine 
CBT: Cognitive Behavioral Therapy 
CBU: Concurrent Benzodiazepine-opioid Use 
CDC: Centers for Disease Control 
CINAHL: Cumulative Index to Nursing and Allied Health Literature  
COT- Chronic Opioid Therapy 
DNP- Doctor of Nursing Practice 
EBP: Evidence Based Project 
EMR: Electronic Medical Record  
JHNEBP: Johns Hopkins Nursing Evidence Based Practice 
NIH: National Institute of Health  
NP: Nurse Practitioner  
PA: Physician Assistant 
PARIHS: Promoting Action on Research Implementation in Healthcare Services  
PICOT: Population Intervention Comparison Outcome Time frame 
PDMP: Prescription Drug Monitoring Program 
UDS: Urine Drug Screen 
USDHHS: United States Department of Health and Human Services  
US: United States 
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APPENDIX A 
 
JHNEBP MODEL AND 
TOOLS- PERMISSION 
 
Thank you for your submission. We are happy to give you permission to use the 
JHNEBP model and tools in adherence of our legal terms noted below: 
 
• You may not modify the model or the tools without written approval from Johns 
Hopkins.  
• All reference to source forms should include “©The Johns Hopkins Hospital/The Johns 
Hopkins University.” 
• The tools may not be used for commercial purposes without special permission.   
If interested in commercial use or discussing changes to the tool, please 
email ijhn@jhmi.edu. 
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APPENDIX B 
Provider Level  CBU  
Yes 
Patient 
Education  
Yes/ No 
Follow Up 
Education 
Yes/ No 
Notes  
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APPENDIX C 
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APPENDIX D 
 
Quarterly Triad Tool (QTT) 
 
Quarterly visit  
 
UDS within 3 months: Y_ N_ 
 
PDMP Consistent: Y_N_ 
 
CBU Identified: Y_N_ 
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APPENDIX E  
 
Provider 
Level  
QTT used 
• QV 
• UDS 
• PDMP 
 
CBU  
Yes 
Patient 
Education  
Yes/ No 
Follow Up 
Education 
Yes/ No 
Notes  
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